CC
CDTX

Caxton Corporation’s Cidara Therapeutics CDTX Stock Holding History

Caxton Corporation’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,040
Closed -$162K – 12
2017
Q1 		$162K Buy
1,040
+22
+2% +$3.86K 0.46% 10
2016
Q4 		$212K Buy
1,018
+97
+11% +$20.2K 0.72% 11
2016
Q3 		$211K Sell
921
-19
-2% -$4.39K 0.94% 8
2016
Q2 		$194K Buy
940
+299
+47% +$72.4K 0.22% 10
2016
Q1 		$163K Hold
641
– – 0.22% 15
2015
Q4 		$220K Buy
+641
New +$192K 0.92% 11

Other funds holding CDTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Caxton Corporation's CDTX Position: Q2 2017 in Review

Caxton Corporation sold out of Cidara Therapeutics (CDTX) in Q2 2017, closing a stake of 1,040 shares — an estimated $162K sold.

Caxton Corporation first reported a position in CDTX in Q4 2015 and held it in 6 quarters. The position peaked at $220K in Q4 2015. 54 funds tracked by Wall St. Rank hold CDTX as of Q2 2017.

  • Caxton Corporation reported no remaining Cidara Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Caxton Corporation sold 1,040 Cidara Therapeutics shares in Q2 2017, an estimated $162K.
  • Caxton Corporation first reported a position in Cidara Therapeutics in Q4 2015 and held it in 6 quarters.
  • Caxton Corporation's Cidara Therapeutics position peaked at $220K in Q4 2015.
  • 54 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2017.

Based on Caxton Corporation's 13F filing for Q2 2017, filed 14 Aug 2017.